The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

Citi keeps a Buy rating on Incyte (INCY) with an $88 price target after the company presented data from its pivotal Phase 3 TRuE-PN1 trial ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Incyte (INCY – Research Report), with a price ...